Hjem › Follikulært lymfom › Tennessee
Follikulært lymfom kliniske forsøg i Tennessee
19 studier for Follikulært lymfom søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT03460977A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- SCRI Oncology Partners ( Site 7000), Nashville
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07634471A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07519772A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Nashville
RekruttererFase 3
Alder 18 til 130 · Alle køn · Opdateret 21. sep. 2026 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Tennessee Oncology, Nashville
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 11. sep. 2026 · NCT06784752A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Vanderbilt University Medical Center, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06091254Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06651177Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07121946The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.